The Atlanta-based company said AMDS is the first aortic arch remodeling device to treat ... 20.9%) New onset renal failure requiring dialysis: 19.4% (vs. 24.1%) Myocardial infarction: 0.0% ...
Principal Financial Group Inc. decreased its position in Artivion, Inc. (NYSE:AORT – Free Report) by 8.1% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 194,630 shares ...
Visualizing the aortic arch and precisely positioning the endoprosthesis is typically ... and the average age of index surgical repair was 14.4 ± 5.4 years. The average interval between the initial ...
First, we carried out proximal aortic root operations, namely, ascending aorta replacement or the Bentall procedure. As stated in our previous studies (21, 22), we employed total arch replacement ...
December 9, 2024—Artivion, Inc. announced that the FDA has granted a humanitarian device exemption (HDE) for the use of the AMDS hybrid prosthesis (formerly known as the Ascyrus Medical dissection ...
The first branch is the right carotid and does not classify as a RAA branching pattern; one may be fooled into believing this is a left aortic arch with the first branch coursing rightward (see ...
Among the many offerings Artivion provides are aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo as well as BioGlue, a polymer that consists of bovine blood protein and an ...
The following is a summary of “Association of aortic root diameter and vascular function with an exaggerated blood pressure ...
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has granted a Humanitarian ...
Background Subclinical leaflet thrombosis (SLT) is a common complication after transcatheter aortic valve replacement (TAVR).
Hydra has less metal in the outflow portion which in turn helps in flexibility and ease of delivery of the frame reducing the chance of trauma to the aortic arch and sealing skirt mitigates ...